Atara Biotherapeutics, Inc. (ATRA)

Trade ATRA now with
12/11/2017 10:07:56 AM Atara Announces Updated Positive Interim Results From Multicenter Expanded Access Study Of Tabelecleucel
11/9/2017 8:27:26 AM Atara Biotherapeutics Q3 Net Losses $31.1 Mln Or $1.02/Shr Vs Loss $25.4 Mln Or $0.88/Shr Last Year
10/19/2017 8:03:10 AM Atara Biotherapeutics Begins 60 Patient, Global Phase 1 Clinical Study To Evaluate Allogeneic ATA188
10/16/2017 8:21:13 AM Atara Reports Abstract Publication For Two MSParis2017 Congress Presentations
9/11/2017 8:06:34 AM Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback For ATA129
9/5/2017 8:08:02 AM Atara Biotherapeutics Receives FDA Orphan Drug Designation For ATA230
6/26/2017 7:26:16 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
3/9/2017 8:17:52 AM Atara Biotherapeutics Q4 Net Loss $18.2 Mln Or $0.63/shr Vs. Loss $21.2 Mln Or $0.75/shr Prior Year
1/3/2017 8:07:24 AM Atara Bio Concludes EMA Scientific Advice And Plans To Submit Conditional MAA In Europe For Allogeneic EBV
12/12/2016 8:08:46 AM Atara Bio Reaches Agreement With FDA On Design Of Phase 3 Trials For Its Lead Anti-Cancer Immunotherapy Program
11/4/2016 8:11:45 AM Atara Biotherapeutics Q3 Net Loss $25.4 Mln Or $0.88/shr Vs. Net Loss $11.9 Mln Or $0.43/shr Last Year
10/18/2016 8:08:12 AM Atara Bio Granted Access To Priority Medicines Regulatory Support For Allogeneic Epstein-Barr Virus
10/11/2016 8:10:32 AM Atara Bio Gets Positive Opinion From EMA On Orphan Drug Designation For CMV-CTL Product Candidate
7/12/2016 8:17:32 AM Atara Bio Doses First Patient In Multi-Center Expanded Access Protocol For Study Of Allogeneic EBV-CTLs